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Abstract
Transcriptional signatures are an indispensible source of correlative information on disease-related molecular alterations
on a genome-wide level. Numerous candidate genes involved in disease and in factors of predictive, as well as of
prognostic, value have been deduced from such molecular portraits, e.g. in cancer. However, mechanistic insights into the
regulatory principles governing global transcriptional changes are lagging behind extensive compilations of deregulated
genes. To identify regulators of transcriptome alterations, we used an integrated approach combining transcriptional
profiling of colorectal cancer cell lines treated with inhibitors targeting the receptor tyrosine kinase (RTK)/RAS/mitogen-
activated protein kinase pathway, computational prediction of regulatory elements in promoters of co-regulated genes,
chromatin-based and functional cellular assays. We identified commonly co-regulated, proliferation-associated target
genes that respond to the MAPK pathway. We recognized E2F and NFY transcription factor binding sites as prevalent
motifs in those pathway-responsive genes and confirmed the predicted regulatory role of Y-box binding protein 1 (YBX1)
by reporter gene, gel shift, and chromatin immunoprecipitation assays. We also validated the MAPK-dependent gene
signature in colorectal cancers and provided evidence for the association of YBX1 with poor prognosis in colorectal cancer
patients. This suggests that MEK/ERK-dependent, YBX1-regulated target genes are involved in executing malignant
properties.
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Introduction
Transcriptional signatures were established for thousands of
cancer specimens and correlated with disease classification,
progression, prognosis and therapy response [1–3]. While the
clinical implications of these data are continuously attracting high
attention, the principles of global disease-related gene deregulation
and their functional consequences are still poorly understood. A
traditional approach for moving correlative gene expression-based
information to the functional level is to select one or few individual
factors from disease-associated signatures and to study the
candidate genes in detail. However, this experimental strategy is
not feasible when hundreds of deregulated genes, or even
combinations of them, need to be analyzed. Investigations of
signaling proteins and other regulatory factors hold great promise,
because such factors can control multiple downstream genes and
therefore potentially qualify as the major drivers of transcriptional
signatures [4–6]. Several lines of evidence have suggested that the
signaling-mediated transcriptional response ultimately involved in
executing cancer phenotypes exhibits a modular organization
[7–10]. Common elements of these modules are proteins of the
signaling network. Transcriptional regulators downstream of the
signaling cascades may either be included among the module
elements or not be components of the gene signature. To
understand the regulatory principles governing cancer-associated
gene signatures, a detailed analysis of such modules is needed.
The receptor tyrosine kinase (RTK)/RAS pathway serves as a
paradigmatic example for studying the functional and regula-
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tory properties of oncogenic signaling networks and their
targets. Many RTK-mediated signals converge on RAS proteins
as major molecular switches for linking cytoplasmic signal
transduction with the underlying genetic program [11]. The
RTK/RAS pathway triggers multiple properties of cancer cells
[12;13]. At the phenotypic level, downstream signaling path-
ways activated by RAS elicit cell type-specific, but also
overlapping effects such as proliferation, cellular survival and
transformation [14–16]. RAS-related gene expression profiles
have been described in various cellular models of malignant
transformation [7;10;17]. More recently, the clinical relevance
of RAS research has been highlighted by the finding that KRAS
mutations cause resistance to therapies targeting membrane-
bound RTKs [18].
Our previous work aimed at cataloguing RAS-responsive target
genes in RAS-transformed fibroblasts and epithelial cells. By
pathway interference using signaling kinase inhibitors, we
identified subsets of target genes (signal-regulated transcriptional
modules) responding to two of the major effector pathways
downstream of RAS, the BRAF/MEK/ERK(MAPK) pathway
and the phosphatidylinositol-3 kinase (PI3K) pathway as well as
subsets of target genes not responding to either pathway [8]. We
assumed that narrowing down the entire gene expression profile to
pathway branch-restricted co-expressed groups of target genes
would be an efficient strategy for identifying regulatory factors
downstream of the signaling cascade. Therefore, we decided to
screen MEK/ERK pathway-controlled transcriptional targets for
common cis-regulatory elements. Computational prediction of
transcription factor binding sites in cis-regulatory elements of
signature genes has been successfully used for a global analysis of
factors mediating immediate-early and delayed transcriptional
responses during transition from the quiescent to the growth
factor-stimulated state [4;5].
To identify transcription factors downstream of the MEK/ERK
pathway, we chose colorectal cancer cell lines as a model rather
than generic cell lines transfected with RAS genes that exhibit
artificially high RAS protein levels. The cell lines harbor
endogenous KRAS or BRAF mutations which drive tumorigenesis
in the colon in concert with further typical genetic alterations in
APC and TP53 genes [19;20]. We analyzed non-synchronized cells
in logarithmic growth phase to avoid extensive overlap with gene
signatures characteristic for growth factor-stimulated transition
from the quiescent to the proliferative state and to mimic the
conditions of cancer cells in various phases of the cell cycle.
In the first step of an integrated analysis, we screened for
responsive target genes in the colorectal cancer cell lines treated
with several inhibitors of the RTK/RAS/RAF/MEK pathway.
Once different sets of pathway-dependent genes were identified,
we subjected the cis-regulatory sequences of clustered target genes
to in silico analysis of potential transcription factor binding sites. In
the second step, we provided biochemical evidence for the specific
role of one of the predicted factors, Y-box binding protein 1
(YBX1), in controlling a significant part of the MEK/ERK(-
MAPK)-dependent transcription of proliferation-associated genes.
Finally, we investigated the MAPK signature and the role of
YBX1 as a prognostic factor in primary and metastatic colorectal
cancers.
Results
Identification of MEK/ERK-dependent targets in
colorectal cancer cells
The transcriptional program in colorectal cancer cells is
profoundly affected by genetic alterations in cellular signaling
systems such as WNT/APC/b-catenin, epidermal growth factor
receptor (EGFR)/RAS/MEK/ERK and DPC4/SMAD4/TGF-
b pathways as well as in transcriptional regulators such as TP53
[20]. Therefore, the identification of transcriptional changes
related to RAS/MAPK signaling required a strategy for
separating the specific from non-MEK/ERK-driven effects. We
used an approach combining expression profiling of three
different tumor cell lines, reflecting the typical genetic back-
ground of primary colorectal cancers, and pathway interference
by inhibitors targeting different elements of the RTK/RAS/
MEK/ERK signal cascade (Figure 1). SW480 cells harbor a
mutation at codon 12 of the KRAS gene, mutated TP53 and APC
tumor suppressor genes. HCT116 cells carry a mutation at codon
13 of KRAS, a CTNNB1 mutation, wild-type TP53 and APC genes.
HT29 cells express wild-type KRAS, and mutated BRAF, TP53
and APC genes [21;22]. To perturb the signaling pathway, we
used the EGFR inhibitor AG1478 [23], two sulindac metabolites,
sulindac sulfide and sulfone known to block RAS/RAF
interaction besides their canonical function as cyclooxygenase-2
inhibitors [24], and the MEK inhibitors PD098059 and U0126
[25;26]. The duration of treatments was at least 48 h to allow
sufficient time for monitoring effects on cellular growth and
survival.
To assess the inhibitor effects on the signaling network, we
determined the phosphorylation status of c-RAF, MEK1/2 and
ERK 1/2. The MEK inhibitor U0126 completely abolished the
phosphorylation of ERK1/2 in all cell lines (Figure 2A), while the
response of the signaling network to the other inhibitors was more
heterogeneous (Figure S1A). These effects ranged from partial
inhibition of the down-stream kinases to unexpected up-regulation
of phosphorylation possibly due to cross-talk or feed-back
mechanisms triggered by transient pathway interference. We
did not observe inhibition of PKB/AKT phosphorylation at
Ser473, indicating that the PI3-kinase pathway was unaffected
(Figure S1B).
We then contrasted the transcriptional profiles of the three cell
lines, treated with each of the five inhibitors separately and a
solvent control by interrogating high-density oligonucleotide
arrays (Affymetrix HG-U133A). To identify groups of co-expressed
Author Summary
The simultaneous analysis of gene expression in cancer
using microarrays is a standard approach for monitoring
disease-related modifications involved in tumorigenesis,
triggering malignant properties and clinical behavior. How-
ever, the factors that drive these alterations most often
remain elusive. We sought to identify transcription factors
that mediate the transcriptional effects of the receptor
tyrosine kinase/RAS oncoprotein pathway, a frequently
activated oncogenic signaling system, in cultured colorectal
cancer cells. We used an integrated approach combining
molecular and functional assays, as well as computational
tools, to identify regulatory factors that trigger the
alterations of gene expression and modulate cellular
growth. We identified the YBX1 protein, a member of the
highly conserved family of cold shock domain transcription
factors, as a regulator of signaling effects triggered by the
RAS cancer gene. Then we assayed the messenger RNA
expression of YBX1 and YBX1-responsive target genes by
interrogating microarrays, and also expression of the YBX1
protein by immunohistochemistry in colorectal tumors. We
found that YBX1 expression is correlated with a bad clinical
outcome in colon cancer patients.
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target genes affected through pathway inhibition, we subjected
7,049 genes (corresponding to 9,272 probe sets exhibiting significant
hybridization intensities) to ArrayMiner clustering. This algorithm
identified 36 clusters of co-regulated genes in the entire set of
pathway interference experiments (Figure 2B, Tables S1 and S2).
Some of the gene clusters reflect cell line-specific responses
dependent on signaling interference (e.g. clusters 07, 16, 28) and
effects independent of pathway inhibition (e.g. clusters 05, 25).
Figure 1. Outline of the experimental design. Outline of the experimental design for exploring the effects of individual elements of the RTK/
RAS/MEK/ERK signaling pathway on the global transcription pattern in colon carcinoma cells. (A) Components of the signaling pathway and their
modulation by inhibitors. Arrows indicate activation, ---o, inhibition. (B) Flow chart of wet lab and computational analysis.
doi:10.1371/journal.pgen.1001231.g001
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Figure 2. Effects of MEK-inhibition on downstream signaling and transcriptomic profiles. (A) Western blot analysis of phosphorylated ERK
levels in colon carcinoma cells treated with the indicated inhibitors for 48 h. DMSO, solvent-only control. Total ERK and b-actin levels were
determined to control for equal loading of cellular lysates. (B) Microarray data (number of target RNA samples = 18) were clustered using the
ArrayMiner algorithm and 36 clusters of co-expressed genes were defined. The numbering of clusters starts with cluster 0 and ends with cluster 35.
The ordinates of each cluster graph represent hybridization intensities on a logarithmic scale. The abscissas of each cluster graph depict the cell lines
and treatments in the same order as in A (from left to right): HCT116 cells treated with DMSO (solvent control), AG1478, sulindac sulfide, sulinac
sulfone, PD98059, and U0126; HT29 cells, treated with the same compounds and SW480 cells, treated in the same way (totaling 3 cell lines with 6
treatments each). Genes in clusters marked by black boxes exhibit strong down-regulation of expression after U0126 treatment and an over-
YBX1 and MEK/ERK-Gene Signatures in Colon Cancer
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However, consistent alterations of gene expression associated with
pathway inhibition were recognized despite the overall transcrip-
tional heterogeneity of the cell lines. Genes down-regulated on
treatment with the MEK inhibitor U0126 represent the largest set of
responsive targets (n = 776) common to all cells (clusters 02, 10, 13,
23; Figure 2B, Table S3). This indicates that the expression of these
genes is sensitive towards MEK/ERK1/2 signaling and, hence,
consistently regulated by this pathway. A Gene Ontology (GO)
analysis of MEK/ERK1/2 target genes revealed a statistically
significant over-representation of functions associated with cell cycle
control (Table S4).
The decisive role of the RAS signaling pathway in triggering
growth, altered differentiation, progression and therapy resistance
of colorectal cancer cells is well established [27;28]. As expected,
representation of gene ontology (GO) terms related to cell cycle regulation, indicating a link between this process and transcriptional control (Table
S3). Genes in clusters marked by bold numbers show over-representation of at least one of further GO terms listed in Table S4. Some of the clusters
reflect cell line-specific differences in gene expression, e.g. genes grouped in clusters 04, 09 were more abundantly expressed in SW480 than in the
two other cell lines, independent of inhibitor treatment. Cluster 04 transcripts encode proteasome components, suggesting a difference in ubiquitin-
dependent protein catabolism between SW480 and other cells. We also detected an overrepresentation of genes associated with development and
morphogenesis in cluster 09. HT29 and HCT116 cells exhibit an epithelial morphology and grow in compact colonies, while SW480 cells show a
spindle-like shape and grow in a scattered fashion until they reach confluence (data not shown). It is likely that cluster 09 genes contribute to these
morphological differences.
doi:10.1371/journal.pgen.1001231.g002
Figure 3. Effects of MEK-inhibition on cell growth and cell cycle progression. (A) Cell growth determined by XTT-based colorimetric assay at
0, 24, 42 and 72 h after adding inhibitors. The mean values for DMSO (control) at 72 hours were set to 100 and all other values were normalized
relative to these values. (B) Flow cytometric analysis of the cell cycle distribution in inhibitor-treated colon carcinoma cells. Black bars, cells in G1
phase; grey bars, S-phase; white bars, G2 phase.
doi:10.1371/journal.pgen.1001231.g003
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treatment with U0126 strongly inhibited growth, mainly due to
blocking the cell cycle in G1 phase (Figure 3A, 3B). Cell cycle
analysis did not reveal any sub-G1 peaks following inhibitor
treatment and we did not observe any morphological changes
indicative of cell death. Thus, apoptosis was excluded as the cause
for reduced cell growth. The other inhibitors exhibited less
consistent effects. PD098059 treatment, sufficient for blocking
MEK1 (IC50 = 4 mM) but not MEK2 (IC50 = 50 mM), reduced
growth of HT29 and SW480, but did not significantly affect
HCT116 cells. Sulindac sulfide and sulfone inhibited growth of
HCT116 and SW480, but not of HT29 cells. This supports the
notion that proliferation in HT29 cells is driven by the BRAF
Figure 4. Predicted biological function and transcription factor binding sites of MEK/ERK pathway-dependent target genes in colon
cancer cells. (A) Heat map of co-regulated genes (clusters 02, 10, 13, 23) in HCT116, HT29 and SW480 cells. Expression values were standardized
separately for each cell line to demonstrate the common pattern of target gene down-regulation after blocking the pathway with the MEK inhibitor
U0126. Green, reduced expression; red, high expression. (B) Fraction of genes attributed to the GO terms ‘‘Cell cycle’’ and ‘‘DNA metabolism’’ in
clusters (white sectors in black circles). Prevalence of transcription binding factor binding motifs for NFY, ELK1, CETS and E2F within gene promoters
at a distance of 200-bp (light yellow sectors in black circles) and 1000-bp (dark yellow sectors) from the transcription start site, respectively. The
statistical significance (p-value) is indicated by asterisks.
doi:10.1371/journal.pgen.1001231.g004
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Figure 5. Role of NFY binding sites in MEK/ERK-dependent gene regulation. (A) Validation of microarray-based expression data (black bars)
by quantitative real-time PCR on TaqMan low density arrays (grey bars). Gene expression data are shown as log2 ratios of RNAs/cDNAs prepared from
HCT116, HT29 and SW480 cells treated with U0126 for 48 hours and DMSO (solvent) controls. (B) CCNB1 promoter activity in transiently transfected
HCT116 cells. The activity of the 257 to +182 bp promoter fragment harboring 2 NFY-binding sites (p240-wt) and controlling the expression of the
chloramphenicol acetylase (CAT) reporter was set to 100%. Light bars indicate CAT expression after U0126 treatment for 48 h, dark bars represent
YBX1 and MEK/ERK-Gene Signatures in Colon Cancer
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mutation and is insensitive to perturbing the RAS/RAF
interaction. AG1478 treatment had no effect, suggesting that
KRAS or BRAF mutations are sufficient for triggering growth and
downstream signaling effects.
Identification of overrepresented transcription factor
binding sites in genes regulated by the MEK/ERK
pathway
To elucidate the potential mechanisms underlying the coordi-
nated expression of MEK/ERK pathway-regulated genes in
colorectal cancer cells, we screened the predicted promoter
regions (1,000 nucleotide sequences upstream of the transcrip-
tional start site of each gene) of all 7,047 informative genes for 559
known transcription factor binding sites assembled in TRANS-
FAC. We compared the number of predicted binding sites in the
promoters of 776 MEK/ERK-dependent genes with their overall
abundance in the entire promoter set. To limit the extent of false
predictions, we used a strict multiple testing framework [29]. As a
result, E2F, NFY and HOXA4 transcription factor binding motifs
occurred significantly more often than expected by chance (Table
S5). The matrix identifiers were E2F1_Q4_01, E2F_Q3_01,
E2F_Q4_01, NFY_01, HOX_A4 and the false discovery rate was
,0.05. Subsequently, we screened the promoter sequences of the
clustered genes separately for overrepresentation of E2F and NFY
binding-motifs. In addition, we investigated the target sequences of
the known MAPK-regulated transcription factors c-ETS and
ELK. The matrix identifiers were E2F1_Q4_01, NFY_01,
CETS1P54_01, and ELK1_02, respectively. E2F and NFY
binding sites were strongly overrepresented in target gene clusters
13 and 23, and NFY motifs solely in cluster 10. C-ETS and ELK
binding motifs were less prevalent, except for ELK1 motifs in
cluster 23. The predicted functional relevance of the recovered
NFY and E2F binding sites in gene clusters 10, 13 and 23 was
further supported by their close proximity (200-bp upstream) to
the transcription start sites of MEK/ERK-dependent genes
(Figure 4).
While the role of E2F transcription factors in RAS-dependent
signal transduction and transformation is well established [30], our
results suggested an important functional relationship between
RAS/MEK/ERK signaling and transcription factor binding to
NFY sites. The core motif RRCCAATSRG is a frequent
regulatory element in eukaryotic promoters and is operative in
forward (CCAAT-box) or reverse orientation (Y-box). To confirm
the functional role of NFY sites in the regulation of proliferation-
associated genes within the clusters, we chose the cyclin B1
(CCNB1) promoter as a model. The CCNB1 protein is a central
regulator of the transition from G2 phase to mitosis. CCNB1
belongs to proliferation-associated cluster 23 (Figure 4). Its
promoter comprises two NFY-binding sites [31]. We verified
CCNB1 mRNA down-regulation following U0126-treatment
independently in all colon carcinoma cell lines (Figure 5A) and
determined CCNB1 promoter activity in transiently transfected
HCT116 cells using a chloramphenicol acetyltransferase (CAT)
reporter gene controlled by the 240-bp promoter fragment
harboring the two NFY-binding sites [32]. U0126 treatment of
HCT116 cells reduced promoter activity to a basal level of 50%
(p-value: ,0.00025, single-sided t-test). The basal activity was
insensitive to MEK inhibition. We observed an equal reduction of
promoter activity using promoter constructs with the two inactive
NFY-binding sites (Figure 5B). Although reporter activity
appeared to be further diminished in cells transfected with the
mutated CCNB1 promoter and treated with U0126, the difference
did not reach statistical significance (p-value: .0.05). Therefore,
MEK inhibition and elimination of NFY binding sites were not
synergistic, indicating that both manipulations mainly affect the
identical mechanism.
To further analyze the influence of upstream MEK signaling on
CCNB1 expression, we stably transfected various MEK expression
constructs into HEK293 cells expressing wild-type RAS. Subse-
quently, CCNB1 promoter activity was determined by transient
transfection of the reporter constructs. Wild-type CCNB1 promoter
activity was strongly enhanced in cells expressing wild-type or
constitutively active MEK1, while the activity of the mutated
promoter did not exceed the basal level (Figure 5C). These results
further supported the critical role of NFY binding sites for MEK-
dependent regulation of CCNB1 mRNA expression.
YBX1 mediates transcriptional effects of RAS/MEK/ERK-
signaling
Since microarray and promoter analysis had suggested a role of
the MAPK pathway and NFY transcription factors in regulating
CCNB1 expression and activity, we decided to further specify
transcription factor:DNA binding. NFY and YBX1 proteins
interact with the NFY-motif [33;34]. SW480, HT29 and
HCT116 cells express YBX1, NFYA and NFYB. U0126
treatment did not consistently alter NFYA, NFYB and YBX1
protein levels (Figure 6A). To find out if any of these factors
preferentially bind to the NFY-element in the CCNB1 promoter,
we performed chromatin immunoprecipitation assays using
nuclear extracts prepared from HCT116 cells and antibodies
specific for YBX1, NFYB and NFYA, respectively. Precipitated
DNA was recovered from immune complexes and subjected to
PCR amplification using primers specific for the 240-bp CCNB1
promoter fragment. The endogenous YBX1 protein preferentially
binds to the CCNB1 promoter in nuclear extracts prepared from all
colorectal cancer cell lines, while we obtained no evidence for
binding of NFYA and NFYB, respectively (Figure 6B).
We confirmed the interaction of YBX1 and the distal NFY-site
in the CCNB1 model promoter by electrophoretic mobility shift
assay (Figure 6C). Two specific YBX1:DNA complexes were
detected in nuclear extracts using a 60-mer oligonucleotide
spanning the NFY-site as binding probe. Pre-incubation with the
N-terminal YBX1-specific antibody prevented complex formation,
while the NFYB-antibody had no effect. Electrophoretic mobility
shifts were efficiently competed by excess of the unlabelled
oligonucleotide. Moreover, YBX1:CCNB1 promoter complex
formation was sensitive to U0126 treatment as shown in nuclear
extracts prepared from HCT116 cells.
YBX1 was previously described as a transcriptional regulator of
CCNB1 in breast cancer cells and in multiple myelomas [35].
However, YBX1 was not linked to CCNB1 expression in other cell
systems, suggesting a tissue-specific function [36]. To test the
impact of YBX1 on CCNB1 expression in colorectal cancer cells,
we transiently silenced YBX1 expression in HCT116 cells by RNA
interference. The knock-down of YBX1 reduced CCNB1 expres-
sion, confirming the role of YBX1 as a CCNB1 regulator in these
DMSO (solvent)-treated controls. Mutated promoters: p240-mP, mutation of proximal NFY-site; p240-mD, mutation of the distal NFY-site; p240-mPD,
double mutant. (C) CCNB1 promoter activity in HEK293 transfectants stably expressing wild-type, constitutively active, dominant negative and kinase-
deficient MEK1 gene constructs, respectively. Activities of the wild-type (p240-wt; dark bars) and mutated (p240-mPD; light bars) CCNB1
promoter:CAT reporters were determined after transient transfection of MEK gene constructs.
doi:10.1371/journal.pgen.1001231.g005
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Figure 6. Regulation of CCNB1 expression by YBX1. (A) Western blot analysis of YBX1 and NFY protein levels in cells treated with the MEK
inhibitor U0126 and controls. 20 mg of whole cell lysates were loaded per lane. The indicated antigens were detected. b-actin was used as a loading
control. (B) Analysis of NFY binding sites of the CCNB1 promoter by chromatin-immunoprecipitation using YB-1, NF-YB and NFYA antibodies. Immune
complexes were prepared from sonicated nuclear extracts prepared from HCT116 cells and PCR-amplification of bound DNA as described in Methods.
A fragment of the GAPDH promoter was used as control. (C) Binding of YBX1 to the CCNB1 promoter analyzed by gel retardation assay. Arrows
indicate the specific retardation of the 60-bp CCNB1 promoter fragment (ns, non-specific binding). Nuclear extracts were prepared from HT29, SW480
(left) and HCT116 cells (right). To assess the dependence on MEK/ERK signaling of YBX1 binding to the CCNB1 promoter, cells were treated with the
MEK inhibitor U0126 and DMSO (solvent control) prior to preparing nuclear extracts. To prove the specificity of binding, we performed the gel
retardation assay with a 100-fold excess of the unlabeled CCNB1 promoter fragment (CCNB1 100x), and in the presence of YBX1 and NFYB antibodies,
respectively. (D) Co-silencing of YBX1 and CCNB1 protein expression in HCT116 cells as revealed by RNA interference. Three independent siRNAs
(YBX1 siRNA1, 2 and 3) targeting YBX1 and scrambled siRNA were transiently transfected. YBX1 protein levels and target CCNB1 expression were
detected by western blotting. b-actin was used as a loading control.
doi:10.1371/journal.pgen.1001231.g006
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cells (Figure 6D). Moreover, silencing of YBX1 resulted in reduced
cell growth, mainly due to a block or a prolongation in G1-phase.
Growth reduction was similar to that of the effects of the MEK
inhibitor U0126 (Figure S2).
To assess the global role of YBX1 as a transcriptional regulator
of MEK/ERK-dependent target genes, we prepared YBX1:chro-
matin immune complexes from HCT116 cells and interrogated
genome-wide promoter tiling arrays (NimbleGen Homo sapiens
HG17 promoter microarray) using the precipitated DNA
fragments as target. We identified DNA fragments enriched by
YBX1-antibody precipitation related to 88 genes of the prolifer-
ation- associated clusters (Table 1, Figure 7). In agreement with
the finding that NFY-binding sites were overrepresented in the
regulatory regions of genes in clusters 10, 13 and 23, we found a
significant overrepresentation of YBX1-ChIP targets in the same
clusters (p-value: ,0.02, Fisher’s exact test). Twenty-six of them
were recently described as potential YBX1 targets in basal-like
breast cancer cells as well [37] (Table 1). Promoter sequences of
two non-YBX1 target genes, GAPDH and LMNA were not
enriched in YBX1:chromatin immune complexes (Figure 7D).
Transcriptional control through YBX1 is linked to
malignant proliferation in colorectal cancer
After identifying target genes of MEK/ERK signaling and
assessing the role of YBX1 in colorectal cancer cell lines, we
analyzed the clinical relevance in colorectal carcinomas. First, we
compared the gene expression profiles of four primary colorectal
tumors, in which YBX1 is up-regulated (Figure 8), with their
matched normal tissues [38]. We identified 851 genes overex-
pressed and 311 genes underexpressed at least two-fold in tumors
relative to their normal controls (Figure S3, Table S6). We found
151 genes of the proliferation-associated clusters, defined in
Table 1. Binding of YBX1 to regulatory sequences of MEK/ERK pathway-dependent target genes.
Gene symbol
fold enrichment
(smoothed)1 Gene symbol
fold enrichment
(smoothed) Gene symbol
fold enrichment
(smoothed)
ACYP1 * 1.5 CDC2 * 1.4 KNTC1 * 2.4
ADH5 * 1.4 CDC2L2 1.5 LPIN1 1.9
ASRGL1 1.7 CGI-01 2.0 MRS2L 1.7
BMS1L * 2.1 CSNK2A1 * 2.0 NHP2L1 1.3
CCNB1 * 1.6 DC12 2.3 NOLC1 1.5
CDK2 1.4 DLEU2 1.6 NSL1 1.3
C14orf156 1.7 DUSP6 1.5 NTAN1 1.6
CREM * 1.8 E1B-AP5 1.7 NXT2 * 1.9
DLG7 * 1.6 ENY2 1.5 OAZ1 * 1.4
FKBP3 1.6 ERH * 1.5 OK/SW-cl.56 1.4
FTSJ3 1.4 FAM98A 2.0 PCNT1 2.1
KIAA0101 * 1.8 FANCG 1.5 PLK4 * 2.1
KIF2C 1.4 FLJ12525 1.4 PMSCL1 1.8
KIFC1 * 1.5 FLJ13912 1.4 PTMA 1.9
METTL3 2.7 FLJ14753 1.5 RACGAP1 1.9
MKI67 * 1.4 FLJ20397 1.6 RCD-8 1.2
MRPL24 3.6 FLJ20399 1.5 RNPS1 1.7
MRPS18A 1.9 FLJ20516 1.8 SEPHS1 2.0
NASP * 1.5 GCN1L1 1.8 SLC39A8 * 1.9
PHF17 1.8 H3F3B * 1.6 SHQ1 1.6
PMVK 1.3 HAN11 3.0 SUPT16H 1.4
PREI3 * 1.4 HNRNPA3 1.5 TMEM194A 1.6
RPA2 * 1.8 HAT1 * 2.1 TTK 1.5
PRPSAP2 * 2.0 HMGN2 1.4 UBAP2L * 1.8
SNRPC 3.7 HPRP8BP 1.9 USP10 * 1.6
TIMM8B 2.0 HSPA8 * 1.5 WBP11 1.7
BIRC5 1.7 HUMGT198A 1.7 ZC3H14 1.5
BMP2K 1.7 KIAA1018 1.5 ZNF207 * 1.6
BUB1B * 1.6 KIAA1393 1.4
C14orf143 2.3 KNSL7 1.4
88 genes initially identified in proliferation-associated clusters were recovered as YBX1 targets by ChIP-on-Chip assay. Twenty-six of them (depicted in bold face) were
also recognized as YBX1 targets in basal-like breast cancer cells [37]. In contrast, only few of the genes in the proliferation-associated clusters were identified by ChIP-on-
Chip assay in HepG2 hepatoma cells (PGRMC1, SLC39A8, RFC3) and in the acute lymphoblastic leukemia line Nalm-6 (RAMP, KIAA0101, PCNA, CENPF) [81], suggesting a
specific role of YBX1 in breast and colorectal cells.
* Genes which show a significant positive correlation to YBX1 expression in colorectal cancers.
doi:10.1371/journal.pgen.1001231.t001
YBX1 and MEK/ERK-Gene Signatures in Colon Cancer
PLoS Genetics | www.plosgenetics.org 10 December 2010 | Volume 6 | Issue 12 | e1001231
Figure 7. Genome-wide analysis of YBX1:DNA binding by chromatin-immunoprecipitation using NimbleGen ChIP-chip microarrays.
The graph on top of the figure represents a schematic illustration of a promoter region (TSS – transcription start side). Extracts of HCT116 cells were
used for ChIP-on-Chip analysis with specific antibodies directed against the C-terminus of YBX1. The Y-axis represents the ratio of hybridization
intensities (on a log2 scale) of YBX1-precipitated DNA and input DNA. Size and number of the bars on the x-axis depict the enrichment of precipitated
DNA fragments around the potential transcription start sites of known (A) and new (B) potential YBX1-target genes. (C) Non-target promoters.
METTL3 (methyltransferase like 3) and SNRPC (small nuclear ribonucleoprotein polypeptide C) were recently identified as potential YBX1 target genes
in basal-like breast cancer cells by ChIP-on-Chip assay [37]. (PCNA: proliferating cell nuclear antigen; HAT1: histone acetyltransferase 1; DUSP6: dual
specificity phosphatase 6; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; ACTN1: actinin, alpha 1).
doi:10.1371/journal.pgen.1001231.g007
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Figure 8. MEK/ERK pathway signature, YBX1 expression, and prognostic value in primary and metastatic colorectal cancer cells. (A)
Venn diagram showing the overlap between genes differentially expressed in primary colorectal tumors and MEK/ERK pathway-dependent,
proliferation-associated target genes identified in colorectal cancer cell lines treated with the MEK inhibitor U0126. The number of the U0126-
responsive genes (523) is smaller than originally identified in the cell lines (776), because there are fewer genes present on the HG-U95A chip
compared to the HG-U133A chip. (B) YBX1 expression in matched pairs of colorectal cancers and normal tissues as detected on Affymetrix HG-U95A
microarrays. (C) Examples of co-expression of YBX1 and YBX1 targets CCNB1 and NASP (nuclear autoantigenic sperm protein) in a set of 43 primary
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colorectal cell lines, to be overexpressed in the tumors (Figure 8A).
None of them were underexpressed.
Next we investigated the relationship between YBX1 expression
and the MEK-dependent, proliferation-associated gene signature
in a larger set of 43 primary colorectal cancers. Overall, the
expression of about 48% of the genes identified in proliferation-
associated clusters was positively correlated with YBX1 expression,
far more than expected by chance (p-value: ,10210, Fisher’s exact
test, Figure S4). The rate of YBX1/signature gene co-expression
was even higher among the 151 genes (74%, corresponding to 111
genes) recovered in the set of matched tumor/normal specimens.
Moreover, we found a significant overrepresentation of U0126-
responsive genes within the group of up-regulated genes in tumors
with high YBX1 expression (193 genes, p-value: ,10210, Fisher’s
exact test). Furthermore, we observed a significant positive
correlation of YBX1 expression with 28 of its target genes
identified by ChIP-on-chip (Figure 8C, Figures S4 and S5,
Table 1). Thirteen YBX1 targets identified in colorectal cancer
cells by chromatin immunoprecipitation were also recovered in a
previous study [37] (Table 1). This robust subset of YBX1 targets
included CCNB1, supporting the crucial role of YBX1 in
proliferation control in colorectal cancer.
Previous studies described the relationship between YBX1
expression and/or nuclear localization of the protein, phenotypic
properties of cancer cells and cancer patient survival [39–46]. To
assess the role of YBX1 as a prognostic factor in colorectal cancer,
we analyzed data from tissue microarrays representing 103
primary colorectal cancers and 15 pulmonary metastases by
immunohistochemistry using an YBX1-specific antibody
(Figure 8D) [45]. We observed a trend that a higher cytoplasmic
YBX1 expression in primary tumors was associated with worse
prognosis, however, the log-rank test failed to reach statistical
significance. Whereas the nuclear expression of YBX1 in primary
tumors was not correlated with patient survival, the nuclear
staining of pulmonary metastases of colorectal cancers was clearly
associated with a worse prognosis, pinpointing the close relation-
ship between YBX1 function, high proliferative potential and poor
outcome of the disease. All statistical values are embedded in
Figure 8E and the clinical data are shown in Table S7.
Discussion
The RTK/RAS/MEK/ERK pathway transduces mitogenic
stimuli and transformed phenotypes through profound alterations of
the transcriptional program. To elucidate regulatory principles of
pathway-triggered gene transcription, we firstly identified common
clusters of target genes sensitive to MEK inhibition in three
colorectal cancer cell lines carrying KRAS or BRAF mutations. Then
we screened target gene promoters for predominantly represented
transcription factor binding sites. By computational analysis we
predicted E2F transcription factors and nuclear factor Y (NFY or
CCAAT-binding factor, CBF) as potential regulators. Since the role
of E2F in growth control is well established [47], we focused on
elucidating the role of NFY-binding motifs, narrowed down the
specific transcription factor binding to them and provided
functional evidence for the role of YBX1 in controlling target gene
expression downstream of MEK/ERK.
Several transcription factors can interact with NFY-binding sites
and regulate diverse or identical targets (reviewed in [48]). For
example, both Y-box binding protein 1 (YBX1) and NFY are
known to be involved in regulating the CCNB1 promoter [33;34].
Reporter assays confirmed that MEK/ERK-dependent stimulation
of transcription is indeed mediated by NFY elements in the CCNB1
promoter. Chromatin immunoprecipitation using NFY-A, NFY-B
or YBX1 antibodies, respectively, revealed that YBX1 preferentially
regulates CCNB1 transcription in colorectal cancer cells. To further
study the role of YBX1 in controlling MEK/ERK-dependent gene
expression, we analyzed endogenous promoter sequences bound to
YBX1 in HCT116 colorectal cancer cells by ChIP-on-chip assay.
Besides CCNB1 we recognized 62 genes within proliferation-
associated gene clusters as YBX1 targets. This supported the notion
that YBX1 is an important regulator of MEK/ERK-dependent
proliferation-associated genes.
YBX1 belongs to the cold-shock domain (CSD) protein super-
family and represents the most evolutionary conserved nucleic acid-
binding protein currently known (for review see [49]). YBX1 exerts
multiple functions including the regulation of transcription [50],
translation [46;51], DNA repair [52], drug resistance [53], cellular
invasion [46;54] and environmental stress response [55]. Several lines
of evidence have indicated that YBX1 promotes proliferation. The
YBX1 protein re-localizes from the cytoplasm into the nucleus in
G1/S-phase of the cell cycle and stimulates expression of cyclin A,
cyclin B1 and other targets [34]. Forced expression of YBX1 in
human mammary epithelial cells (HMEC) induced EGF-indepen-
dent proliferation via activation of the EGFR pathway, presumably
by direct transcriptional stimulation of EGFR gene expression rather
than via autocrine stimulation [56]. Targeted disruption of YBX1
alleles resulted in major defects in the G2/M phase [57], suppression
of cell proliferation in cancer cells, associated with a reduction of cells
in S-phase of the cell cycle [36], multi-organ hypoplasia and
senescence in response to cellular stress [58]. YBX1 transgene
expression in mammary glands of lactating mice resulted in early
onset of hyperplastic growth followed by progression to carcinomas
[59]. Over-expression of YBX1 in breast [53], prostate [60] and colon
cancer [61] confirmed its role as a positive modulator of proliferation.
The cis-regulatory sequences of genes down-regulated on
blocking the MEK/ERK pathway in colorectal cancer cells
clearly differ from those of growth factor stimulated genes which
for example harbor binding sites for the transcription factors
ATF/CREB, NFkB and SRF [4;5]. While growth factor
stimulation permitted the identification of primary effectors of
the signaling cascade, our approach is more likely to identify
primary and secondary consequences of a chronic RASMEK/
ERK pathway activation. NFY-binding sites were not recovered in
the promoters of growth factor-regulated genes. The MEK/ERK
target gene clusters 13 and 23 only share binding sites for ELK
and E2F transcription factors with the growth factor-regulated
module. This suggests that the transcription factors ELK and E2F
may be essential for both initiating and maintaining proliferative
potential during transition from the quiescent to the proliferative
colorectal tumors as detected on Affymetrix HG-U95A microarrays. Discordant expression of YBX1 and non-target ACTN1 (actinin, alpha 1) shown in
the same tumor set. Pearson correlation coefficients (coef) and p-values are inserted in the graphs. Further examples of YBX1 targets are shown in
Figure S4. (D) Expression of YBX1 in colorectal tumor sections assembled on tissue microarrays. TMAs were analyzed by immunohistochemical
staining using peptide-specific antibodies directed against the N-terminus of YBX1. Cytoplasmic and nuclear staining was scored independently.
Score 0, negative for YBX1 expression, score 1, intermediate expression; score 2, high expression. (E) Kaplan-Meier plots showing the association
between YBX1 expression and overall patient survival. Left: predominant cytoplasmic YBX1 expression in primary tumors; middle: nuclear YBX1
expression in primary tumors; right: nuclear YBX1 expression in pulmonary metastasis. Clinical data are shown in Table S7.
doi:10.1371/journal.pgen.1001231.g008
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state [47], while YBX1 serves a different function in growth
control. The diversity of growth factor-stimulated effects and
MEK/ERK-dependent effects in continuously cycling cells was
also reflected at the target gene expression level. We identified
dual-specificity phosphatase (DUSP6) as the only factor commonly
regulated by YBX1 and the set of transcription factors involved in
growth factor-induced stimulation. DUSP6 is involved in feedback
regulation of the MAPK pathway and is necessary to shape its
biological activity regardless of its initial mode of activation [62].
Several lines of evidence have already indicated a close
relationship between YBX1 function and the RTK/RAS pathway
including ERK and AKT, the downstream effectors of RAS. YBX1
cooperated with the AKT pathway to transform mammary
epithelial cells [63]. YBX1 was identified as a direct target of
RSK1 and RSK2, a group of kinases downstream of ERK [64].
YBX1 can also be phosphorylated directly via ERK and by GSK3b
[65]. Notably, treatment of basal-like breast cancer cells with the
MEK inhibitor PD98059 resulted in the inhibition of YBX1
function [65] and the knock-down of YBX1 in breast cancer cells
harboring activated RAS resulted in growth suppression [66]. The
effects of the MEK inhibitor U0126, which completely blocked
MEK/ERK activity, and the growth inhibition observed in the
HCT116 cell line following the silencing of YBX1 expression
support the notion that the effects on YBX1 are likely to be
mediated by ERK and/or RSK1/2 in colorectal cancer cells.
High YBX1 expression and/or nuclear localization are closely
associated with poor prognosis in several types of cancer [39–44].
Therefore, we sought to define a YBX1-related target gene
signature in colorectal cancer. About 29% of the genes in
proliferation- associated clusters are up-regulated in primary
colorectal cancer samples compared to matched normal tissue,
demonstrating the relevance of the MEK/ERK-dependent
expression signatures and the YBX1 regulator for colorectal
cancer biology. The expression of YBX1 in primary colorectal
carcinomas correlated well with the expression of YBX1 target
genes including CCNB1, which are involved in cell cycle control.
Higher levels of nuclear YBX1 expression in pulmonary metastasis
were associated with poor outcome in colorectal cancer patients.
We assume that this is due to highly proliferative metastatic cells.
In contrast to the consequences of the MEK inhibitor U0126, the
effects of the sulindac metabolites are more difficult to understand.
These inhibitors interfere with RAS signaling, however, are not
sufficient to block MEK/ERK during a period of 48 hrs.
Alterations of the CRAF phosphorylation status after sulindac
metabolite treatment point at cellular feedback mechanisms that
may be responsible for sustained MAPK activity. The observation
that the two sulindac metabolites affect growth effect in HCT116
and SW480 cells indicates that additional effectors of the signalling
system may contribute to the overall proliferative potential.
In summary, we have combined signaling interference,
transcriptomic profiling and computational analysis of cis-
regulatory elements of target genes to identify YBX1 as a
transcriptional regulator downstream of the mitogen-activated
protein kinase (MEK/ERK) pathway. The results reported in this
paper prove the feasibility of utilizing pathway-restricted gene
expression data and computational analysis of genomic DNA
adjacent to transcriptional start sites for elucidating regulatory
principles. Moreover, the data define necessary future studies to
close the gap between understanding the role of a single factor in
controlling deregulated gene expression in cancer cells and the
comprehension of gene regulation at the systems level. Specific
pathway inhibitors, neutralizing antibodies and siRNAs are useful
tools for dissecting networks in further detail, particularly for
linking groups of transcriptional targets (or modules) and defined
branches of signaling pathways. Several layers of complexity will
have to be further analyzed, presumably at the level of individual
transcription factor targets. Future work will have to address the
combinatorial effects of E2F and YBX1/NFY transcription factors
[30;67], the dual role of YBX1 in controlling transcription and
translation of mRNA targets, the role of YBX1 phopshorylation
through ERK2 and AKT [51;63;65], and the biological function
in regulating cellular growth in cell lines, tumors and metastases.
Methods
Cell lines and cell culture
The colon carcinoma cell lines SW480, HT29 and HCT116
were cultured in complete L15 medium at 37uC and 5% CO2 in a
humidified incubator. To block RAS-mediated signal transduction
the following inhibitors, dissolved in DMSO (final concentration:
0.29%), were added to the medium for 48 h at the indicated
concentrations: EGFR inhibitor AG 1478 (300 nM), RAS/RAF
interaction inhibitors sulindac sulfide (100 mM) and sulindac
sulfone (200 mM; all Merck Biosciences GmbH, Schwalbach,
Germany), MEK inhibitors PD098059 (16 mM; Alexis Deutsch-
land GmbH, Gru¨nberg, Germany) and U0126 (20 mM; Promega
GmbH, Mannheim, Germany). Control cultures were adjusted to
the same DMSO concentration as inhibitor-treated cells. Follow-
ing treatments, cells were directly lysed in a buffer containing 1%
SDS, 10 mM Tris/HCl, pH = 7.5, and 2 mM EDTA.
Proliferation assays
One thousand cells were seeded in 96-well plates and incubated
with medium containing inhibitors or DMSO only for 24–72 hr.
Growth of cells was determined in triplicate experiments by a
colorimetric XTT-based assay (Roche Diagnostics GmbH,
Mannheim, Germany). The XTT reagent was prepared and
added to cells in 24 h intervals according to the manufacturer’s
protocol. After 4 h of incubation we determined the extinction at
480 nm. All extinction measurements were calculated relative to
the DMSO-control after 72 hr. The means of at least three
independent experiments are presented.
Immunoblots
Ten mg of whole cell lysates per lane were fractionated by SDS-
PAGE and blotted onto nitrocellulose membranes (Schleicher and
Schuell, Dassel, Germany). The following antibodies were used for
specific protein detection: cyclin B1, ERK2, a-CBFA (NFYB) and
a-CBFB (NFYA) (Santa Cruz Biotechnology, Santa Cruz, USA),
P-C-RAF, P-MEK, P-ERK (Cell Signalling Technology, Beverly,
USA), ERK1 (BD Biosciences, Heidelberg, Germany), YBX1
(peptide specific N- and C-terminal antibodies). Secondary
antibodies coupled to horseradish peroxidase were used in
combination with the ECL detection system (Amersham Biosci-
ences, Freiburg, Germany).
Cell cycle analysis
To determine the cell cycle distribution of inhibitor-treated cells,
both adherent and floating cells were collected, washed twice in
phosphate-buffered saline, and fixed in 70% ethanol. Samples
were stored at 4uC. Prior to flow cytometry, samples were
centrifuged, the supernatants were discarded and the remaining
pellets suspended in dilution buffer (0.1% Triton X-100, 0.5%
BSA in phosphate buffered saline) supplemented with 80 mg/ml
DNase-free RNase (Roche Diagnostics, Mannheim, Germany).
Samples were incubated at room temperature for 30 min. RNase
was removed by centrifugation and cell pellets were stained with
20 mg/ml propidium-iodide (Fluka, Heidelberg) in dilution buffer.
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Cell suspensions were analyzed by flow cytometry on a FACS
Calibur system (BD Biosciences, Heidelberg, Germany). Single cell
populations were gated from the received dot blots using WinMDI
software (V. 2.8; Joseph Trotter; freeware) and the resulting
histograms further analyzed for cell cycle distribution with using
Cylchred software (V. 1.0.0.1; UWCM). All measurements were
performed in duplicate.
Microarray analysis
The HG-U133A human oligonucleotide microarray (Affymetrix,
Santa Clara, CA, USA) comprises 22,283 known genes. Labeling of
RNA targets, hybridization and post-hybridization procedures were
performed according to protocols provided by Affymetrix. Follow-
ing washing and staining, probe arrays were scanned twice at 3 mm
resolution using a confocal argon laser scanner (Hewlett-Packard,
Santa Clara, CA), controlled by Microarray Suite 5.0 software
(Affymetrix). Photoemission was detected by a photomultiplier tube
through a 570-nm long-pass filter. Computer-generated array
images were overlaid with a virtual grid, controlled by Microarray
Suite 5.0 software. This step allowed definition of each feature and
alignment within known array dimensions. About 40 pixels within
each feature were averaged after discarding outliers and pixels close
to feature boundaries. Gene expression levels were calculated
according to the average hybridization intensities of perfectly
matched versus mismatched oligonucleotide probes. Arrays were
scaled by Microarray Suite 5.0 software to an average hybridization
intensity of 2,500 per gene and analyzed independently. The Data
Mining Tool 3.0 (Affymetrix) and GeneSpring software package 6.1
(Silicon Genetics, Redwood City, CA) were used for comparing
expression profiles of inhibitor-treated colorectal cancer cell lines
and DMSO controls. The data were normalized to compensate for
variability in hybridizations and hybridization artifacts.
Validation of array expression data by quantitative real-
time PCR
cDNAs of selected target genes were obtained by reverse
transcription of 2 mg of total RNA using the High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, USA). PCR
amplification was done on TaqMan low density arrays using the
ABI PRISM 7900HT Sequence Detection System (384-well
format) according to the manufacturer’s instructions (http://
www.appliedbiosystems.com). Primers were synthesized by Ap-
plied Biosystems (Table 2). We used SDS2.2-analysis software
(Applied Biosystems) for quantification. RNA prepared from
DMSO-treated cells was used as the calibrator sample and
GAPDH primers as endogenous control detector.
GO-analysis
To identify potential biological functions associated with gene
clusters, we analyzed the Gene Ontology (GO) annotations of co-
expressed genes. To avoid redundant sequence representations, we
mapped the probe set identifiers of significantly detected probe sets
and gene clusters to LocusLink identifiers. These were annotated
with GO-terms using HomGL [68], available at http://homgl.
gene-groups.net. To test the biological processes represented in
Gene Ontology for significant overrepresentation in annotated
gene clusters as compared to the set of all expressed genes, we
applied the GOSSIP algorithm [69], available at http://gossip.
gene-groups.net. We chose the significance threshold such that the
false discovery rate was below 5%.
In silico promoter analysis
Potential regulatory regions of all genes that entered the cluster
analysis ranging from 1-kb upstream to the transcription start site
of the longest transcript were extracted from the human genome
database version NCBI35, Ensembl version 30 [70]. These regions
were scanned for all 559 motifs of known transcription factor
binding sites represented as positional frequency matrices in
Transfac version 9.4 [71] using a published algorithm [72].
Overrepresentation of binding sites in clusters was determined by
estimating the false discovery rate (FDR) using the hyper-
geometric distribution as described [29]. A threshold of FDR
,0.05 was applied and FDR was validated by running the same
analyses on 100 randomly chosen clusters of the same size. All
genes that entered the cluster analysis were used as a reference set.
Transient transfection of CCNB1 reporter genes
Chloramphenicol acetyl transferase (CAT) reporter plasmids
harboring either the CCNB1 promoter from nucleotides 257 to
+182 (p240B1-CAT) or the same fragment with mutations in both
NFY-binding sites (p240B1mPX-CAT [32]) were transiently
transfected into HCT116 cells. The pCAT3-Basic vector and
mock transfections served as controls. Transfer efficiency was
controlled by transfection of pCAT-control, a reporter construct
harboring the SV40 promoter (BD Biosciences, Heidelberg,
Germany). The conditions for transfections and analysis of
reporter gene activity by CAT enzyme linked immunosorbent
assay were described previously [55]. To assess the effect of
MAPK signal transduction on CCNB1 promoter activity, trans-
fected HCT116 cells were treated with 20 mM U0126 for 48 h.
The amount of CAT protein in transfectants was normalized to
the protein content of the corresponding cellular lysate and
expressed as % CAT expression relative to that of p240B1-CAT
transfections. Values are given as average of duplicate transfec-
tions from 2 independent experiments.
Chromatin immunoprecipitation (ChIP)
The ChIP-assay was done as described with modifications [73].
In brief, 26106 cells were plated prior to U0126-treatment for
48 h. To compensate for the higher proliferation rate, 16106 cells
Table 2. Validation of gene expression by real-time RT-PCR.
Gene symbol HG-U133A-ID Taqman Assay-ID
AURKB 209464_at Hs00177782_m1
CCNB1 214710_s_at Hs00259126_m1
CCNB2 202705_at Hs00270424_m1
CDC2 203213_at Hs00176469_m1
CDC25C 205167_s_at Hs00156411_m1
CDK2 204252_at Hs00608082_m1
CDKN3 209714_s_at Hs00193192_m1
CHEK1 205394_at Hs00176236_m1
CKS2 204170_s_at Hs00854958_g1
HMMR 209709_s_at Hs00234864_m1
MKI67 212020_s_at Hs00606991_m1
PCNA 201202_at Hs00427214_g1
Pfs2 221521_s_at Hs00211479_m1
RFC2 1053_at Hs00267983_m1
RFC3 204127_at Hs00161357_m1
15 genes initially identified in proliferation-associated clusters were selected for
validation using Taqman Q-PCR. The table summarizes the gene symbols and
the corresponding Affymetrix-IDs and Taqman-Assay-IDs.
doi:10.1371/journal.pgen.1001231.t002
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treated with solvent only were plated in parallel. Following fixation
and removal of the cytoplasm, nuclei were re-suspended in 600 ml
nuclear lysis buffer (50 mM Tris/HCl, pH 8.0, 10 mM EDTA,
1% SDS and protease inhibitors). Two treated samples were
combined and sonicated. After centrifugation, the supernatants
were transferred into new tubes and the DNA content was
determined by spectrophotometry at 260 nm. An equivalent of
100 mg DNA per sample was diluted 1:10 in a buffer containing
20 mM Tris/HCl pH = 8.0, 150 mM NaCl, 2 mM EDTA, 1%
Triton X100 and protease inhibitors and incubated with 4 mg of
the following antibodies for 16 h: a-YBX1 (directed aginst a c-
terminal peptide of YBX1) [74], a-CBFA (NFYB) (sc-7711x) and
a-CBFB (NFYA) (sc-7712x) (both from Santa Cruz Biotechnology,
Santa Cruz, USA), a-V5 (Invitrogen, Karlsruhe, Germany).
Protein-A-agarose was added for 60 min to collect antibodies
and bound DNA:protein complexes. The beads were washed 3-
times with low salt buffer (20 mM Tris/HCl pH = 8.0, 150 mM
NaCl, 2 mM EDTA, 1% Triton, 0,1%SDS), and once with high
salt buffer (20 mM Tris/HCl pH = 8.0, 500 mM NaCl, 2 mM
EDTA, 1% Triton, 0,1%SDS). The precipitated DNA:protein
complexes were eluted by incubation with 0,1 M NaHCO3, and
1%SDS. NaCl was added to a final concentration of 200 mM and
the samples were incubated at 65uC for 4 h. DNA was extracted
with phenol/chloroform and precipitated using ‘‘Pelletpaint’’ for
16 h. The pellets were diluted in 40 ml pure water and 2,5 ml-
aliquots were subjected to 35 cycles of PCR using an Advantage 2
system (BD Bioscience). The following primers were used for the
amplification of promoter-specific DNA fragments: CCNB1
(fragment –142 to +57): forward primer (59-AGAGGCAGAC-
CACGTGAGAG-39), reverse primer (59-GCCAGCCTAGCCT-
CAGATTTA-39); GAPDH (fragment –908 to –603): forward
primer (59-GGATGGAATGAAAGGCACAC-39), reverse primer
(59-GTTTCTGCACGGAAGGTCAC-39).
For a genome-wide analysis of YBX1:DNA binding we took
advantage of the NimbleGen array service including labeling of
probes and array hybridization. Preparations for ChIP-on-chip
probes from HCT116 cells were done according to NimbleGen
protocols (supplied by RZPD, Berlin, Germany). Amplification of
precipitated DNA and input control was carried out essentially as
described [75] with one round of PCR amplification (20 cycles)
followed by a second round (10 cycles). Amplified DNA was
purified using the QIAquick PCR purification kit (Quiagen)
according to the manufacturer’s instructions. The raw hybridiza-
tion intensities of each channel of the array (NimbleGen Homo
sapiens HG17 promoter) were normalized and log-transformed
using Bioconductor VSN package [76]. Fold changes were
calculated by subtraction of Cy3 (input) from Cy5 intensity (ChIP
sample). Normalized probe levels were smoothed along chromo-
somal coordinates using a sliding window method. For each probe
position the smoothed probe level was computed as the median
over the probe levels in an 800-bp window centered at that
position. A cut-off was defined for enriched probes assuming a
normal distribution of the smoothed data and calculating the 86%
quantile. Enriched probes were merged into enriched regions, if
less than 600-bp apart. Resulting regions of at least five probes
were called enriched sites. The statistical significance of YBX1-
ChIP target over-representation in clusters 10, 13 and 23 was
determined by Fisher’s exact test. A p-value below 0.05 was
considered significant.
Electrophorectic mobility shift assay
Nuclear extracts were prepared using the nuclear extraction kit
(Pierce, Rockford, USA) according to the manufacturer’s instruc-
tions. Three mg of each nuclear extract were used in a binding
assay with 20 fmol of a biotin-labeled single-stranded oligonucle-
otide derived from the CCNB1 promoter (59-CTGGAAACG
CATTCTCTGC GACCGGCAGCC GCCAATGGGA AGG-
GAGTGAG TGCCACGAAC-39). For competition experiments a
100-fold excess of the same unlabelled oligonucleotide was added.
The presence of YBX1 in the retarded DNA:protein complexes
was confirmed by adding 2 mg of a-YBX1 N-terminal antibody or
an unrelated control antibody a-CBFA (NFYB) (Santa Cruz
Biotechnology, Inc., Santa Cruz, USA). The binding reactions
were incubated at 30uC for 15 min before adding the labeled
oligonucleotide. After further incubation of 30 min the samples
were fractionated by electrophoresis through a 6% SDS-
polyacrylamide gel. The biotin-labeled oligonucleotides were
visualized after transfer onto a nylon membrane by incubation
with streptavidin-horseradish peroxidase conjugate according to a
standard protocol (Pierce, Rockford, USA).
Analysis of MEK-dependent gene signatures and YBX1
expression in primary colon carcinomas and metastases
Expression data (obtained by interrogating Affymetrix HG-
U95A microarrays) of primary colorectal carcinomas and
matched normal colonic tissue were selected from a previously
published study [38]. Differentially regulated genes were
determined with the SAM algorithm (Significance analysis of
microarrays; [77]) using the ‘‘samr’’ package [78] provided in the
software environment ‘‘R’’ for statistical computing and graphics
(version R 2.9, [79]). The delta value was set to obtain a false
discovery rate (FDR) of ,0.05 and the threshold of fold changes
was set to $2.
Furthermore, we divided all primary colorectal cancers into two
groups according to their YBX1 expression: tumours with YBX1
expression less than the mean (low expressing group); tumours
with YBX1 expression higher than the mean (high expressing
group). We identified differentially expressed genes using ‘‘samr’’
with a false discovery rate (FDR) of ,0.05. The over-represen-
tation of U0126-responsive genes in tumours with high YBX1
expression was determined using Fisher’s exact test. A p-value
,0.05 was considered significant.
Pearson correlation coefficients of YBX1 expression and the
expression of genes represented on the Affymetrix HG-U95A
array were calculated for 43 primary colorectal cancers charac-
terized in the same study using R 2.9. A p-value ,0.05 was
considered to indicate a significant correlation.
To be able to compare the expression data obtained from cell
lines (analyzed by interrogating HG-U133A microarrays) with
those from the tumor samples, we extracted a matched list of genes
represented on both types of microarrays. A total of 532 genes
responsive to U0126 treatment were also represented on the HG-
U95A chip platform.
Immunohistochemical scores of cytoplasmic and nuclear YBX1
expression in primary colon carcinoma and pulmonary metastases
and survival data were selected from a previous tissue microarray
analysis [45]. Kaplan-Meyer curves were calculated and plotted
using the package ‘‘survival’’ [80] in R (version 2.9). The design
and processing of tissue microarrays was essentially as described
previously [45].
Silencing of YB-1 expression by siRNA
Specific siRNA against YB-1 (ID # 115541 and 115542) as well
as an unrelated control siRNA (Silencer Negative control # 1
siRNA, Cat# 4611) were obtained from Ambion (Austin, USA).
Two transfection systems were used in this study: a) HCT116 cells
were plated and cultured for 24 h and then transfected twice in an
interval of 24 h with the specific or control siRNA at a final
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concentration of 5 gM using oligofectamine (data shown in
Figure 6D). b) HCT116 cells were transfected using siPORT
Amine according to the manufacturer’s protocol (Ambion, Austin,
USA) (data shown in Figure S2).
Microarray data sets
Microarray data sets are available at http://www.ncbi.nlm.nih.
gov/geo/under accession codes GSE18232 and GSE18337.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Robert-Ro¨ssle-Clinic, Berlin-
Buch. All patients provided written informed consent for the
collection of samples and subsequent analysis. This study does not
include any animal experiments.
Supporting Information
Figure S1 Inhibitor effects on oncogenic signaling pathways in
colorectal cancer cells. (A) Western blot analysis of c-RAF
phosphorylated at Ser256 (P-c-RAF), total c-RAF, P-MEK1/2
and P-ERK levels in colon carcinoma cells treated with the
indicated inhibitors for 48 h. DMSO, solvent-only control. Total
ERK and b-actin levels were determined to control for equal
loading of cellular lysates. Heterogeneous effects of inhibitors other
than the MEK-inihibitor U0126: PD098059 showed a partial
reduction of phosphorylated ERK1/2 after 48 h and the other
inhibitors had no effect. MEK phosphorylation was not signifi-
cantly changed after this period of time, but there were distinct
alterations in the c-RAF status. The sulindac metabolites caused
an increase of c-RAF phosphorylation at Ser256 in SW480 and a
partial increase in HT29 cells. Treatment of HCT116 cells with
the same compounds resulted in two different forms of
phosphorylated c-RAF. AG1478 and PD098059 showed weak
effects, while the U0126 incubation resulted in a reduction of c-
RAF phosphorylation in HT29 cells as well as in diminished RAF
protein levels in HCT116 and SW480 cells, respectively. (B)
Western blot analysis of P-AKT levels in colon carcinoma cells
treated with the indicated inhibitors for 48 h. DMSO, solvent-only
control. (loading control: total AKT levels).
Found at: doi:10.1371/journal.pgen.1001231.s001 (1.09 MB TIF)
Figure S2 Effects of YBX1 knock-down on cell growth and cell
cycle distribution. (A) Proliferation of HCT116 cells was measured
after transfection with YBX1 specific or scrambled siRNAs using
the XTT assay. The treatment with transfection reagents alone is
shown as mock control. Scr, scrambled siRNA (control). *, p-value:
,0.025, single-sided T-test). (B) Proliferation of HCT116 cells
(XTT assay) transfected with increasing amounts of scrambled or
YBX1-specific siRNA. *, **, p-values: ,0.025 and ,0.0025,
respectively. (C) Flow cytometric analysis of cell cycle distribution
of HCT116 cells after siRNA transfection. For ease of comparison,
bar diagram includes data obtained with the DMSO solvent
control and U0126 treatment shown in Figure 3B.
Found at: doi:10.1371/journal.pgen.1001231.s002 (0.59 MB TIF)
Figure S3 Differentially expressed genes in four matched pairs
of normal and tumor tissue as determined by SAM analysis. False
discovery rate ,0.05, fold change .2; red: up-regulated genes;
green: down-regulated genes. The list of differentially expressed
genes is shown in Table S6.
Found at: doi:10.1371/journal.pgen.1001231.s003 (0.22 MB TIF)
Figure S4 Correlation of MEK/ERK-dependent target gene
and YBX1 expression in colorectal cancer. We generated 100
random sets of 151 (A), 523 (B) and 851 genes (C), respectively,
from the genes represented on the Affymetrix HG-U95A
microarray. The size of the gene sets corresponds to (A) the
number of proliferation-associated genes up-regulated in four
colon tumors relative to their matched normal tissues, (B) to the
number of proliferation-associated genes identified in clusters 02,
10, 13, 23 and (C) to all genes up-regulated in four colon tumors
relative to their matched normal controls, respectively. For each
set, we calculated the fraction of genes showing a significant
positive or negative (discordant) correlation with YBX1 expression
in the set of 43 primary colorectal cancers and displayed the
frequencies graphically. The red dots mark the fraction of positive
or negative correlations in the experimentally defined sets.
Found at: doi:10.1371/journal.pgen.1001231.s004 (0.47 MB TIF)
Figure S5 Coexpression of YBX1 and YBX1-target genes.
Supplement to Figure 8C. Further examples of YBX1 and YBX1
target co-expression in 43 primary colorectal tumors as detected
on Affymetrix HG-U95A microarrays. YBX1 targets shown in (A)
were also identified in basal-like breast cancer cells (Ref. 37;
Finkbeiner, M.R., Astanehe, A., To, K., Fotovati, A., Davies,
A.H., Zhao, Y., Jiang, H., Stratford, A.L., Shadeo, A., Boccaccio,
C., Comoglio, P., Mertens, P.R., Eirew, P., Raouf, A., Eaves, C.J.,
and Dunn, S.E. [2009]. Profiling YB-1 target genes uncovers a
new mechanism for met receptor regulation in normal and
malignant human mammary cells. Oncogene 28: 1421–1431). (B)
Novel YBX1 targets. Pearson correlation coefficients (coef) and p-
values are inserted in the graphs.
Found at: doi:10.1371/journal.pgen.1001231.s005 (0.35 MB TIF)
Table S1 Normalized expression values obtained by microarray
analysis of colorectal cancer cell lines treated with inhibitors.
Columns indicate the probe set-ID on Affymetrix HG-U95A
microarrays, gene symbol, number of cluster (see Figure 3) and the
normalized expression values of all 18 experiments with 3 cell
lines, 5 inhibitor treatments and DMSO (solvent) control.
Found at: doi:10.1371/journal.pgen.1001231.s006 (2.09 MB
XLS)
Table S2 Statistical features of gene clustering were obtained by
calculating the distance of each gene to the center of the cluster
(parameter: in) and the distance to the center of the closest other
cluster (parameter: out). The fit coefficient was computed using the
formula: abs (out minus in)/(out plus in).
Found at: doi:10.1371/journal.pgen.1001231.s007 (1.75 MB
XLS)
Table S3 Table of genes in U0126-responsive clusters. Affyme-
trix probe-set ids, gene symbols and normalized expression of
genes in cluster 02, 10, 13 and 23.
Found at: doi:10.1371/journal.pgen.1001231.s008 (2.04 MB
XLS)
Table S4 List of overrepresented Gene Ontology (GO) terms
related to the products of clustered target genes. Columns indicate
the cluster number, GO-identifier, GO-term and false discovery
rate (FDR) calculated by the GOSSIP algorithm (Ref. 69;
Blu¨thgen, N., Brand, K., Cajavec, B., Swat, M., Herzel, H., and
Beule, D. [2005]. Biological profiling of gene groups utilizing gene
ontology. Genome Inform 16: 106–115). In addition, the last four
columns show the number of genes in each cluster corresponding
to the GO-term, the number of genes with the GO-term not
present in the cluster, genes without the GO-term in the cluster,
and all genes without the GO-term, not present in the cluster.
Found at: doi:10.1371/journal.pgen.1001231.s009 (0.04 MB
XLS)
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Table S5 Prediction of transcription factor binding sites. The
procedure for identifying transcription factor binding sites in the
regulatory sequences of MEK/ERK pathway-regulated genes is
described in Materials and Methods. Columns indicate probe set-
IDs, gene symbols, the number of the cluster of co-expressed genes
and the predicted binding sites for NFY, E2F and HOX4A
(marked by ***).
Found at: doi:10.1371/journal.pgen.1001231.s010 (1.88 MB
XLS)
Table S6 Differential gene expression in four colorectal cancers
and matched normal tissues. SAM analysis of microarray data
(Affymetrix HG-U95A), FDR ,0.05, fold change .2.
Found at: doi:10.1371/journal.pgen.1001231.s011 (0.23 MB
XLS)
Table S7 Clinical data of tissue microarray study. Data
collection and description of technique: Ref. 45; Kno¨sel T, Emde
A, Schlu¨ns K, Chen Y, Ju¨rchott K, Krause M, Dietel M, Petersen
I. (2005). Immunoprofiles of 11 biomarkers using tissue micro-
arrays identify prognostic subgroups in colorectal cancer. Neopla-
sia. 7:741–747. Columns of table: T, TNM stage; N, nodal status;
M, metastasis, 0, no metastasis, 1, metastatic tumor; G, grade.
Immunohistochemical detection of YBX1 protein in cytoplasm
and nucleus; 0, no staining; 1, weak, 2 intermediate, 3, strong
staining (see Figure 8D for an example). Death: 0, patient alive at
the time of analysis; 1, patient deceased. Survival time indicated in
weeks.
Found at: doi:10.1371/journal.pgen.1001231.s012 (0.03 MB
XLS)
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